Advertisement
Advertisement
U.S. Markets open in 5 hrs 10 mins
Advertisement
Advertisement
Advertisement
Advertisement

ACADIA Pharmaceuticals Inc. (ACAD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.00-0.64 (-4.37%)
At close: 04:00PM EDT
14.01 +0.01 (+0.07%)
After hours: 07:29PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close14.64
Open14.62
Bid0.00 x 1400
Ask0.00 x 1000
Day's Range13.88 - 14.72
52 Week Range12.24 - 28.06
Volume2,721,367
Avg. Volume2,609,209
Market Cap2.251B
Beta (5Y Monthly)0.52
PE Ratio (TTM)N/A
EPS (TTM)-1.20
Earnings DateFeb 22, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.89
  • Motley Fool

    Why Acadia Pharmaceuticals Stock Is Crashing Today

    An FDA advisory committee voted against recommending approval for pimavanserin in treating Alzheimer's disease psychosis.

  • Benzinga

    Why Acadia Pharma Shares Are Plunging Today

    A panel of the FDA's outside experts voted 9-3 that Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin doesn't appear to be effective at treating patients with Alzheimer's-related psychosis. The drug, Nuplazid, is already indicated for Parkinson's-related psychosis. Acadia tried and failed last year to get another FDA approval for Alzheimer's psychosis. Related: Acadia Stock Drops After FDA CRL For Pimavanserin Application In Hallucinations and Dementia-Related Psychosis. "We are disappoin

  • MarketWatch

    Acadia's stock down 30% in premarket trading on Tuesday after last week's FDA committee vote

    Shares of Acadia Pharmaceuticals Inc. were still down 30.5% in premarket trading on Tuesday, days after a Food and Drug Administration advisory committee voted against approval of the company's treatment for hallucinations and delusions associated with Alzheimer's disease psychosis. The committee on Friday voted 9-3 that the benefits of pimavanserin do not outweigh the risks. The FDA, which is not required to follow the advice of the committee but often does, is expected to decide whether to app

Advertisement
Advertisement